A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The commercial launch of Casgevy continues to gain momentum ... At the same time, RNA molecules made in a lab could guide Cas proteins to exactly where to cut the DNA. The technique works in ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in ...

This study shows that RNA decay rather than the presence of premature termination codons triggers a TA-like response.

In late 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) for sickle cell disease (SCD), marking the world ...

Researchers at Martin Luther University have developed groundbreaking RNA-based agents that offer high levels of protection ...